CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Symptom resolution with MMX® mesalazine in patients with mild-to-moderately active ulcerative colitis who are newly diagnosed or have been living with their disease for a prolonged period
DOI 10.1055/s-0030-1263695
Bibliografische Angaben
Nachweis in CareLit
Autor:innenD Solomon, W Sandborn, M Kamm, G Lichtenstein, K Barrett
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2010
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: Ulcerative colitis, (UC) causes patients a number of disruptive and distressing symptoms. While treatment should aim to resolve the underlying source of the disease, in the short term, symptom resolution is an important goal for patients. Objectives: Here, we examine the efficacy of MMX® mesalazine (Mezavant®, Shire Pharmaceuticals Inc, USA; MMX; Cosmo Technologies Ltd, Ireland) for resolving increased…
Zitieren
Zitierempfehlung
D Solomon, W Sandborn, M Kamm, G Lichtenstein, K Barrett (2010) Symptom resolution with MMX® mesalazine in patients with mild-to-moderately active ulcerative colitis who are newly diagnosed or have been living with their disease for a prolonged period. Zeitschrift für Gastroenterologie (08). https://doi.org/10.1055/s-0030-1263695
Mit CareLit weiterarbeiten